Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Senti Biosciences ( (SNTI) ).
On March 17, 2026, Senti Biosciences, Inc. amended its main Alameda, California lease to cut its occupied space in half to about 45,955 square feet effective September 1, 2025, reducing base rent and its share of operating expenses and taxes, while allowing the landlord to draw $2.0 million from an existing letter of credit in exchange for the lower rent and a reduced credit requirement. A parallel sublease amendment with GeneFab, LLC aligned the subtenant’s rent and expense obligations with the revised master lease, shifted a $1.0 million reduction fee to GeneFab, and created a structure allowing GeneFab’s outstanding and future rent obligations to be worked off through services for Senti, tightening the financial linkage between the two firms and clarifying default risks tied to GeneFab’s performance.
The most recent analyst rating on (SNTI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Senti Biosciences stock, see the SNTI Stock Forecast page.
Spark’s Take on SNTI Stock
According to Spark, TipRanks’ AI Analyst, SNTI is a Neutral.
The score is held down primarily by very weak financial performance (no meaningful revenue, substantial losses/cash burn, and rising leverage with compressed equity). Technicals also remain bearish with the stock trading below major moving averages, partially offset by near-oversold RSI. A positive clinical-data/RMAT corporate event provides upside optionality but does not offset the current funding and profitability risks.
To see Spark’s full report on SNTI stock, click here.
More about Senti Biosciences
Senti Biosciences, Inc. is a biotechnology company focused on research and development activities carried out at its laboratory and office facilities in Alameda, California. The company’s operations rely on leased research and development and laboratory space, including premises that are partially subleased to GeneFab, LLC, to support its scientific and corporate functions.
Average Trading Volume: 235,036
Technical Sentiment Signal: Sell
Current Market Cap: $25.51M
See more data about SNTI stock on TipRanks’ Stock Analysis page.